已上市凝血因子VIII产品的比较分析:重组产品在可溶性蛋白聚集体和亚可见颗粒方面并不相同
该研究分析了9种重组凝血因子VIII(rFVIII)产品在复溶后以及使用相关应激条件下的可溶性蛋白聚集体(SPA)和亚可见颗粒(SVP)浓度。结果显示所有产品均含不同浓度的SPA和SVP,SPA浓度范围为0.2%至11.6%,SVP为0.7×10^6至114.0×10^6/1000 IU;在应激条件下产品形成额外SPA和SVP的程度不同,提示产品质量决定其形成倾向,并凸显市售rFVIII产品间的差异。
要点
- 复溶后所有rFVIII产品均含SPA和SVP,浓度范围分别为0.2%–11.6%和0.7×10^6–114.0×10^6/1000 IU。
- 使用相关应激条件(振荡和剪切)下,各产品形成额外SPA和SVP的程度不同。
- 产品质量决定其形成SVP和SPA的倾向,市售rFVIII产品间存在差异。
核心结论
- 收集的数据表明,产品质量决定其形成SVP和SPA的倾向,并凸显了市售rFVIII产品之间的差异。
研究设计与样本
- 分析了9种rFVIII产品(每种至少3个批次),采用高效液相色谱-尺寸排阻色谱(HPLC-SEC)和基于流式细胞术的颗粒分析。
主要发现
- 所有新鲜复溶的rFVIII产品中均存在不同浓度的SPA和SVP:SPA浓度范围为0.2%至11.6%;SVP为0.7×10^6至114.0×10^6/1000 IU。
- 在使用相关应激条件(振荡和剪切应力)下,产品以不同程度形成额外的SPA和SVP。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Aggregation is a critical quality attribute of protein therapeutics influencing immunogenicity. Aggregates and subvisible particles in 9 recombinant factor VIII (rFVIII) products were analyzed. Major differences in aggregate and particle concentrations were detected after reconstitution. rFVIII product quality determined aggregation propensity under use-relevant stress. SUMMARY: Background Recombinant protein technologies have facilitated the development of novel factor VIII (FVIII) therapeutics with improved production efficiency, potency and half-live, and a low risk of viral transmission. The increasing number of recombinant FVIII (rFVIII) products and information on their efficacy, safety and cost allow patients and healthcare professionals to adjust treatment to individual needs. Nonetheless, 20-32% of previously untreated patients with severe hemophilia A develop inhibitory antibodies to rFVIII following treatment. The root cause of the immunogenicity of rFVIII products is not well understood. Data for human interferon and human insulin products suggest that critical quality parameters such as soluble protein aggregates (SPAs) and subvisible particles (SVPs) influence the immunogenicity of protein therapeutics. Therefore, we analyzed SPA and SVP concentrations in commercially available rFVIII products and determined how these parameters change upon exposure of rFVIII products to relevant stress conditions. Objectives Compare critical quality parameters such as SPA and SVP concentrations in rFVIII products under intended use and use-relevant stress conditions. Methods Nine rFVIII products (≥ 3 lots each) were analyzed by high-performance liquid chromatography-size exclusion chromatography (HPLC-SEC) and flow cytometry-based particle analysis. Results/conclusions SPAs and SVPs were present at different concentrations in all freshly reconstituted rFVIII products: SPA concentrations ranged from 0.2% to 11.6%; SVPs were 0.7 × 106 to 114.0 × 106 / 1000 IU. Under use-relevant stress conditions (agitation and shear stress) the products formed additional SPAs and SVPs to different degrees. The collected data indicate that product quality determines its propensity to form SVPs and SPAs, and highlights differences between marketed rFVIII products.
引用
- Anzengruber J, Lubich C, Prenninger T, et al. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles. J Thromb Haemost. 2018. PMID: 29665242. doi:10.1111/jth.14125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。